Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
bevacizumab + tandutinib
- Development stage
- Unknown
- Lead developer
- Millennium Pharmaceuticals
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Oral
01
Overview
Bevacizumab + tandutinib is a combination therapy that targets multiple aspects of tumor vasculature. Tandutinib (MLN518) is a piperazinyl quinazoline receptor tyrosine kinase inhibitor that inhibits the autophosphorylation of FLT3, c-KIT, and PDGF receptor tyrosine kinases. Bevacizumab is an anti-VEGF monoclonal antibody. The combination was investigated primarily for its potential to enhance antitumor activity by targeting both VEGF (via bevacizumab) and PDGFR/c-KIT (via tandutinib) pathways, capitalizing on the concept of targeting tumor vasculature through multiple mechanisms.
02
Targets
PDGFR (PDGFR family)VEGFA (Vascular endothelial growth factor A)FLT3 (Fms related receptor tyrosine kinase 3)KIT (c-KIT proto-oncogene receptor tyrosine kinase)
Beyond the preview
Go deeper on bevacizumab + tandutinib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on bevacizumab + tandutinib.